• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Dengue - Pipeline Review, H1 2012 Product Image

Dengue - Pipeline Review, H1 2012

  • ID: 2092605
  • March 2012
  • 92 pages
  • Global Markets Direct

Dengue – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dengue - Pipeline Review, H1 2012', provides an overview of the Dengue therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. 'Dengue - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dengue.
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dengue Overview
Therapeutics Development
An Overview of Pipeline Products for Dengue
Dengue Therapeutics under Development by Companies
Dengue Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Dengue Therapeutics – Products under Development by Companies
Dengue Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Dengue Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
Biotron Limited
Alfacell Corporation
AVI BioPharma Inc.
Medivir AB
NanoViricides, Inc.
SIGA Technologies, Inc.
Phynova Group Ltd
MacroGenics, Inc.
Canopus BioPharma Incorporated
Inviragen, Inc.
Dengue – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PYN18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Antiviral Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBV-001 D1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB5300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DengueCide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DENVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rDEN1delta30 Dengue Virus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rDEN3/4delta30(ME) Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rDEN4delta30-4995 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rDEN4delta30-200,201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rDEN3-3'D4delta30 Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue-1 Premembrane/Envelope DNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Type 2 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetravalent Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TetraVax-DV Vaccine-Admixture 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TetraVax-DV Vaccine-Admixture 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DEN4 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monocloncal Antibodies For Pathogens - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Virion Dengue - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Anti-Virals - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Fever Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVI-6006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Fever Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS3 Protease Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Squalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAmphinase 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V180 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Therapeutics – Drug Profile Updates
Dengue Therapeutics – Discontinued Products
Dengue Therapeutics - Dormant Products
Dengue – Product Development Milestones
Featured News & Press Releases
Dec 07, 2011: Inviragen Presents Safety And Immune Response Data From Phase I Study Of Two-Dose Dengue Vaccine, DENVax At ASTMH Meeting
Nov 28, 2011: Inviragen Initiates Phase II Clinical Study Of DENVax
Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses
Nov 04, 2010: Sanofi Pasteur’s Dengue Vaccine Enters First Phase III Clinical Study
Oct 25, 2010: Inviragen Initiates DENVax Phase I Clinical Testing In Colombia
Sep 14, 2010: Themis Bioscience And Institut Pasteur Form R&D Alliance To Fight Tropical Infectious Diseases Including Dengue
Jul 19, 2010: Tamir's Compounds Show Remarkable Results Against Dengue Virus
Jul 19, 2010: Tamir's Compounds Show Remarkable Results Against Dengue Virus
May 19, 2010: Inviragen’s Dengue Vaccine to Begin Clinical Testing
Mar 26, 2010: Hawaii Biotech Discusses Dengue Vaccine Developement At Brazil Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dengue, H1 2012
Products under Development for Dengue – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
GlaxoSmithKline plc, H1 2012
Merck & Co., Inc., H1 2012
Biotron Limited, H1 2012
Alfacell Corporation, H1 2012
AVI BioPharma Inc., H1 2012
Medivir AB, H1 2012
NanoViricides, Inc., H1 2012
SIGA Technologies, Inc., H1 2012
Phynova Group Ltd, H1 2012
MacroGenics, Inc., H1 2012
Canopus BioPharma Incorporated, H1 2012
Inviragen, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dengue Therapeutics – Drug Profile Updates
Dengue Therapeutics – Discontinued Products
Dengue Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Dengue, H1 2012
Products under Development for Dengue – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos